Peritoneal Cancer

• CLINICAL_TRIALS trial_result · 2024-01-10
  Clinical Trial Update: Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian Cancer [Phase 1, Phase 2]

  Phase 1/2 trial evaluating avelumab with or without entinostat in advanced epithelial ovarian cancer and peritoneal cancer has completed; re…

• CLINICAL_TRIALS trial_result · 2023-12-11
  Clinical Trial Update: Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer [Phase 1, Phase 2]

  A Phase 1/2 clinical trial evaluating pazopanib hydrochloride with paclitaxel and carboplatin in patients with refractory or resistant ovari…

• CLINICAL_TRIALS trial_result · 2023-12-07
  Clinical Trial Update: Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi [Phase 2]

  Phase 2 trial evaluating fluzoparib with or without apatinib in platinum-sensitive relapsed ovarian cancer previously treated with PARP inhi…

• CLINICAL_TRIALS trial_result · 2023-11-27
  Clinical Trial Update: Intraoperative Intraperitoneal Chemoperfusion to Treat Peritoneal Minimal Residual Disease in Stage III Ovarian Cancer [Phase 2]

  Phase 2 trial evaluating intraoperative intraperitoneal chemoperfusion for treating minimal residual disease in stage III ovarian cancer and…

• CLINICAL_TRIALS trial_result · 2023-11-07
  Clinical Trial Update: Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Epithelial Ovarian Cancer (EOC). [Phase 2]

  Phase 2 trial of pembrolizumab with paclitaxel and carboplatin in advanced epithelial ovarian cancer (and fallopian tube/peritoneal cancers)…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS trial_result · 2023-10-26
  Clinical Trial Update: Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT) [Phase 3]

  A Phase 3 trial of Upifitamab Rilsodotin (Upifitamab Rilsodotin) in maintenance therapy for platinum-sensitive recurrent ovarian cancer has …

• CLINICAL_TRIALS trial_result · 2023-10-13
  Clinical Trial Update: Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer [Phase 2]

  Phase 2 trial evaluating the addition of tremelimumab to olaparib for recurrent ovarian, fallopian tube, or primary peritoneal cancer; the s…

• CLINICAL_TRIALS trial_result · 2023-10-04
  Clinical Trial Update: TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors [Phase 1]

  Phase 1 results for a study combining the TORC1/2 inhibitor MLN0128 (sapanisertib) with bevacizumab in adults with recurrent glioblastoma or…

• CLINICAL_TRIALS trial_result · 2023-09-15
  Clinical Trial Update: Autologous T Cells With or Without Cyclophosphamide and Fludarabine in Treating Patients With Recurrent or Persistent Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer (Fludarabine Treatment Closed as of 12/01/2009) [Phase 1]

  Phase 1 trial evaluating autologous T cells with or without cyclophosphamide and fludarabine for recurrent or persistent advanced ovarian ep…

• CLINICAL_TRIALS trial_result · 2023-09-08
  Clinical Trial Update: Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer [Phase 2]

  Phase 2 clinical trial update evaluating gemcitabine hydrochloride with or without the WEE1 inhibitor adavosertib in patients with recurrent…

• CLINICAL_TRIALS trial_result · 2023-08-07
  Clinical Trial Update: BEACON - ABC in Recurrent Platinum Resistant HGSOC [Phase 2]

  Phase 2 trial update for BEACON program in recurrent platinum-resistant high-grade serous ovarian cancer (HGSOC).

• CLINICAL_TRIALS trial_result · 2023-07-19
  Clinical Trial Update: Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer [Phase 1, Phase 2]

  Clinical trial update of veliparib combined with topotecan hydrochloride in adults with solid tumors, relapsed or refractory ovarian cancer,…

• CLINICAL_TRIALS trial_result · 2023-05-24
  Clinical Trial Update: Oregovomab and PLD in PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment [Phase 2]

  A Phase 2 clinical trial investigating oregovomab and pegylated liposomal doxorubicin (PLD) in patients with PARP inhibitor–resistant ovaria…

• CLINICAL_TRIALS trial_result · 2023-05-06
  Clinical Trial Update: A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208) [Phase 2]

  Phase 2 safety-run-in update for weekly tisotumab vedotin in platinum-resistant ovarian cancer (innovaTV 208) completed, with results posted…

• CLINICAL_TRIALS trial_result · 2023-05-06
  Clinical Trial Update: IP ALT-803 Followed by SQ ALT-803 for Ovarian Cancer [Phase 2]

  Phase 2 trial evaluating ALT-803 administered subcutaneously after initial ALT-803 treatment for ovarian cancer, fallopian tube cancer, and …

• CLINICAL_TRIALS trial_result · 2023-04-21
  Clinical Trial Update: Cyclophosphamide With or Without Celecoxib in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer [Phase 2]

  Phase 2 trial evaluating cyclophosphamide with or without celecoxib in recurrent/persistent ovarian epithelial, fallopian tube, or primary p…

• CLINICAL_TRIALS trial_result · 2023-03-28
  Clinical Trial Update: Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer [Phase 2]

  Phase 2 clinical trial update on the combination of cediranib and olaparib for recurrent cancers of the fallopian tube, ovary, or peritoneum…

• CLINICAL_TRIALS trial_result · 2023-03-24
  Clinical Trial Update: MITO 35a: Olaparib Maintenance Therapy in Newly Diagnosed BRCA Wild-type Advanced Ovarian, Fallopian Tube and Primitive Peritoneal Cancer [Phase 2]

  Phase 2 trial update of olaparib maintenance therapy in newly diagnosed BRCA wild-type advanced ovarian, fallopian tube, and primary periton…

• CLINICAL_TRIALS trial_result · 2023-03-24
  Clinical Trial Update: Pembrolizumab With Chemotherapy in Front Line Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer [Phase 2]

  Phase 2 trial update evaluating pembrolizumab in combination with chemotherapy as frontline treatment for advanced ovarian, primary peritone…

• CLINICAL_TRIALS trial_result · 2023-03-17
  Clinical Trial Update: A Study of the Efficacy and Safety of Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer [Phase 3]

  This Phase 3 trial evaluated bevacizumab in addition to standard therapy for newly diagnosed Stage III/IV epithelial ovarian, fallopian tube…

• CLINICAL_TRIALS trial_result · 2023-01-30
  Clinical Trial Update: Trial of Pembrolizumab Following Weekly Paclitaxel for Platinum-resistant Ovarian, Fallopian Tube or Peritoneal Cancer [Phase 2]

  Phase 2 trial evaluating pembrolizumab after weekly paclitaxel in platinum-resistant ovarian, fallopian tube, or peritoneal cancer.

• CLINICAL_TRIALS trial_result · 2023-01-19
  Clinical Trial Update: Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer [Phase 2]

  Phase 2 clinical trial evaluating irinotecan liposome with bevacizumab for platinum-resistant or recurrent ovarian, fallopian tube, or prima…

• CLINICAL_TRIALS trial_result · 2022-12-29
  Clinical Trial Update: Bevacizumab Plus Modiifed FOLFIRINOX in Ovarian, Fallopian Tube, or Primary Peritoneal Mucinous Carcinoma [Phase 2]

  Phase 2 clinical trial evaluating bevacizumab with modified FOLFIRINOX for mucinous ovarian, fallopian tube, or primary peritoneal cancers.

• CLINICAL_TRIALS trial_result · 2022-11-21
  Clinical Trial Update: A Single-arm Clinical Trial of IMGN853 in Chinese Adult Patients With Platinum-resistant, Epithelial Ovarian Cancer [Phase 3]

  A single-arm Phase 3 trial of IMGN853 in Chinese adults with platinum-resistant epithelial ovarian cancer is ongoing, with conditions includ…

• CLINICAL_TRIALS trial_result · 2022-10-25
  Clinical Trial Update: Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer [Phase 2]

  Phase 2 clinical trial evaluating gemcitabine hydrochloride alone or in combination with M6620 for recurrent ovarian, fallopian tube, or pri…